Acadian Asset Management
MRKR icon

Acadian Asset Management’s Marker Therapeutics MRKR Stock Holding History

Acadian Asset Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,186
Closed -$5K – 1878
2022
Q4 		$5K Hold
2,186
– – ﹤0.01% 1748
2022
Q3 		$8K Hold
2,186
– – ﹤0.01% 1640
2022
Q2 		$7K Sell
2,186
-1,765
-45% -$5.87K ﹤0.01% 1651
2022
Q1 		$17K Hold
3,951
– – ﹤0.01% 1581
2021
Q4 		$37K Buy
+3,951
New +$52.5K ﹤0.01% 1529

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAM
AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MAA
Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management's MRKR Position: Q1 2023 in Review

Acadian Asset Management sold out of Marker Therapeutics (MRKR) in Q1 2023, closing a stake of 2,186 shares — an estimated $5K sold.

Acadian Asset Management first reported a position in MRKR in Q4 2021 and held it in 5 quarters. The position peaked at $37K in Q4 2021. 30 funds tracked by Wall St. Rank hold MRKR as of Q1 2023.

  • Acadian Asset Management reported no remaining Marker Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Acadian Asset Management sold 2,186 Marker Therapeutics shares in Q1 2023, an estimated $5K.
  • Acadian Asset Management first reported a position in Marker Therapeutics in Q4 2021 and held it in 5 quarters.
  • Acadian Asset Management's Marker Therapeutics position peaked at $37K in Q4 2021.
  • 30 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2023.

Based on Acadian Asset Management's 13F filing for Q1 2023, filed 11 May 2023.